NO20083793L - Antistoffer mot amyloid-beta peptid - Google Patents

Antistoffer mot amyloid-beta peptid

Info

Publication number
NO20083793L
NO20083793L NO20083793A NO20083793A NO20083793L NO 20083793 L NO20083793 L NO 20083793L NO 20083793 A NO20083793 A NO 20083793A NO 20083793 A NO20083793 A NO 20083793A NO 20083793 L NO20083793 L NO 20083793L
Authority
NO
Norway
Prior art keywords
antibodies
amyloid
beta peptide
methods
elevated
Prior art date
Application number
NO20083793A
Other languages
English (en)
Norwegian (no)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Stephen Anthony Burbidge
Susannah K Ford
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20083793L publication Critical patent/NO20083793L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20083793A 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid NO20083793L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
PCT/EP2007/052928 WO2007113172A2 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
NO20083793L true NO20083793L (no) 2008-10-13

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083793A NO20083793L (no) 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid

Country Status (32)

Country Link
US (3) US8227576B2 (de)
EP (2) EP1996621B1 (de)
JP (1) JP5103466B2 (de)
KR (2) KR101263294B1 (de)
CN (2) CN103539857A (de)
AR (1) AR060332A1 (de)
AT (1) ATE451392T1 (de)
AU (1) AU2007233831B2 (de)
BR (1) BRPI0709246A2 (de)
CA (1) CA2647808C (de)
CR (1) CR10347A (de)
CY (1) CY1109877T1 (de)
DE (1) DE602007003703D1 (de)
DK (2) DK1996621T3 (de)
EA (1) EA015654B9 (de)
ES (2) ES2338179T3 (de)
HR (2) HRP20100115T1 (de)
IL (1) IL193695A (de)
JO (1) JO2576B1 (de)
MA (1) MA30337B1 (de)
MX (1) MX2008012483A (de)
MY (1) MY149630A (de)
NO (1) NO20083793L (de)
NZ (1) NZ571038A (de)
PE (1) PE20080181A1 (de)
PL (2) PL2177536T3 (de)
PT (2) PT1996621E (de)
SI (2) SI1996621T1 (de)
TW (1) TWI385179B (de)
UA (1) UA94734C2 (de)
WO (1) WO2007113172A2 (de)
ZA (1) ZA200807911B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) * 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
WO2009024567A1 (en) * 2007-08-20 2009-02-26 Glaxo Group Limited Production method
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
BRPI0818621A8 (pt) * 2007-10-05 2018-01-30 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
MX2010003622A (es) * 2007-10-12 2010-04-14 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
UY31520A1 (es) * 2007-12-11 2009-08-03 Proteinas de union a antigenos
EP2261254A3 (de) * 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
AR072359A1 (es) 2008-05-06 2010-08-25 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
EP2346906A4 (de) 2008-10-15 2013-04-24 Angiochem Inc Konjugate aus glp-1-agonisten und ihre verwendung
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
EP2421562B1 (de) 2009-04-20 2019-03-13 Angiochem Inc. Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
EP2308897A1 (de) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
AP2012006359A0 (en) 2010-03-03 2012-08-31 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
AU2013266611B2 (en) 2012-05-21 2016-08-11 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
EP3011343A2 (de) 2013-06-19 2016-04-27 Glaxosmithkline Intellectual Property (No. 2) Limited Test für komplementfaktor-i (cfi)-bioaktivität
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
US11530257B2 (en) 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
EP3819311A4 (de) * 2018-07-17 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta-antikörper, antigenbindendes fragment davon und verwendung davon
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
CN1177616C (zh) * 1997-04-09 2004-12-01 曼德塞特生物制药公司 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6428950B1 (en) * 1998-11-25 2002-08-06 Scios Inc. Assay to identify compounds that alter apolipoprotein E expression
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
DE60134430D1 (de) * 2000-11-03 2008-07-24 David Gladstone Inst Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
PL377769A1 (pl) * 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje

Also Published As

Publication number Publication date
JO2576B1 (en) 2011-02-27
EP1996621B1 (de) 2009-12-09
EA015654B9 (ru) 2012-01-30
HK1122311A1 (en) 2009-05-15
IL193695A0 (en) 2011-08-01
MX2008012483A (es) 2008-10-10
WO2007113172A3 (en) 2007-11-29
HRP20100115T1 (hr) 2010-04-30
EP2177536B1 (de) 2014-06-04
CA2647808A1 (en) 2007-10-11
IL193695A (en) 2012-05-31
EA015654B1 (ru) 2011-10-31
DK2177536T3 (da) 2014-07-14
PE20080181A1 (es) 2008-03-16
AU2007233831A1 (en) 2007-10-11
DK1996621T3 (da) 2010-04-19
PL1996621T3 (pl) 2010-05-31
SI2177536T1 (sl) 2014-09-30
JP5103466B2 (ja) 2012-12-19
SI1996621T1 (sl) 2010-04-30
KR101263294B1 (ko) 2013-06-04
US8227576B2 (en) 2012-07-24
WO2007113172A2 (en) 2007-10-11
TWI385179B (zh) 2013-02-11
UA94734C2 (ru) 2011-06-10
CN103539857A (zh) 2014-01-29
AU2007233831B2 (en) 2013-02-14
BRPI0709246A2 (pt) 2011-07-12
CY1109877T1 (el) 2014-09-10
PT2177536E (pt) 2014-08-22
AR060332A1 (es) 2008-06-11
CR10347A (es) 2008-10-29
DE602007003703D1 (de) 2010-01-21
ES2484967T3 (es) 2014-08-12
PL2177536T3 (pl) 2014-11-28
EP1996621A2 (de) 2008-12-03
US9193784B2 (en) 2015-11-24
HRP20140618T1 (hr) 2014-08-15
CN101415729A (zh) 2009-04-22
TW200815466A (en) 2008-04-01
KR20080113273A (ko) 2008-12-29
ATE451392T1 (de) 2009-12-15
US20160024197A1 (en) 2016-01-28
CA2647808C (en) 2015-11-17
EA200801842A1 (ru) 2009-02-27
US20110142824A1 (en) 2011-06-16
HK1138015A1 (en) 2010-08-13
MA30337B1 (fr) 2009-04-01
PT1996621E (pt) 2010-03-08
ES2338179T3 (es) 2010-05-04
JP2009531380A (ja) 2009-09-03
EP2177536A1 (de) 2010-04-21
ZA200807911B (en) 2009-11-25
US20140050719A1 (en) 2014-02-20
MY149630A (en) 2013-09-13
KR20120093400A (ko) 2012-08-22
NZ571038A (en) 2011-03-31
CN101415729B (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
NO20083793L (no) Antistoffer mot amyloid-beta peptid
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
IN2014CN03936A (de)
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
GEP20115324B (en) Tweak binding antibodies
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EP2650308A3 (de) Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenerkrankungen
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
BRPI0513798A (pt) anticorpos anti-cd154
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EP2586795A3 (de) Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
EA202190387A1 (ru) Антитело к cd38 человека и его применение
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
HK1132751A (en) Compositions and methods relating to glucagon receptor antibodies

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application